{"id":9,"date":"2025-11-20T23:45:08","date_gmt":"2025-11-21T04:45:08","guid":{"rendered":"https:\/\/genopsy-us.com\/?page_id=9"},"modified":"2026-02-17T23:15:25","modified_gmt":"2026-02-18T04:15:25","slug":"landing-page","status":"publish","type":"page","link":"https:\/\/genopsy-us.com\/","title":{"rendered":"Landing page"},"content":{"rendered":"<div class=\"et_pb_section_0 et_pb_section et_section_regular et_block_section\">\n<div class=\"et_pb_row_0 et_pb_row et_block_row\">\n<div class=\"et_pb_column_0 et_pb_column et_pb_column_4_4 et-last-child et_block_column et_pb_css_mix_blend_mode_passthrough\">\n<div class=\"et_pb_text_0 et_pb_text et_pb_bg_layout_light et_pb_module et_block_module preset--module--divi-text--c16985e1-e0d6-4022-964d-e2bfc04fa633\"><div class=\"et_pb_text_inner\"><h1>A new era of lung cancer diagnostics<\/h1>\n<\/div><\/div>\n\n<div class=\"et_pb_text_1 et_pb_text et_pb_bg_layout_light et_pb_module et_block_module preset--module--divi-text--1f09816e-184e-4ce5-a4cf-b39c52c423ca\"><div class=\"et_pb_text_inner\"><h2>Unlocking better patient care by using precision medicine to accelerate clinical decision-making.<\/h2>\n<\/div><\/div>\n<\/div>\n<\/div>\n\n<div class=\"et_pb_row_1 et_pb_row et_flex_row\">\n<div class=\"et_pb_column_1 et_pb_column et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_12_24 et_flex_column_12_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_text_2 et_pb_text et_pb_bg_layout_light et_pb_module et_block_module preset--module--divi-text--b327cbe4-b1d5-4b66-ad37-40c8f2f061ba\"><div class=\"et_pb_text_inner\"><h2>About Genopsy<\/h2>\n<\/div><\/div>\n\n<div class=\"et_pb_text_3 et_pb_text et_pb_bg_layout_light et_pb_module et_block_module preset--module--divi-text--1f09816e-184e-4ce5-a4cf-b39c52c423ca\"><div class=\"et_pb_text_inner\"><div class=\"message-body\">\n<div class=\"message-body\">\n<p>Genopsy is a preclinical-phase diagnostics company developing a platform to detect lung cancer\u2013associated molecular signatures with high sensitivity and near-real-time clinical decision support.<\/p>\n<p style=\"font-weight: 400;\">Our novel diagnostic platform integrates:<\/p>\n<ul>\n<li>First-in-class, nanowire-based biosensing architecture (not PCR-based)<\/li>\n<li>Multi-analyte detection from a single blood sample<\/li>\n<li>Rapid analytical processing with a 2-hour turnaround<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n<div class=\"et_pb_column_2 et_pb_column et-last-child et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_12_24 et_flex_column_12_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_image_0 et_pb_image et_pb_module et_flex_module\"><span class=\"et_pb_image_wrap\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/11\/1130-animated-compositeillustration.gif\" width=\"720\" height=\"720\" sizes=\"(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) 720px, 100vw\" class=\"wp-image-233\" \/><\/span><\/div>\n<\/div>\n<\/div>\n\n<div class=\"et_pb_row_2 et_pb_row et_flex_row\">\n<div class=\"et_pb_column_3 et_pb_column et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_16_24 et_flex_column_16_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_text_4 et_pb_text et_pb_bg_layout_light et_pb_module et_flex_module preset--group--divi-text--divi-font-body--default\"><div class=\"et_pb_text_inner\"><p>Unlike conventional, sequencing-based or single-analyte assays, Genopsy\u2019s platform is designed to detect lung cancer\u2013associated molecular signatures with high analytical sensitivity, while enabling near-real-time clinical decision support and longitudinal monitoring.<\/p>\n<p>Genopsy is establishing its U.S. regulatory and commercialization presence, with development conducted in partnership with academic labs and CDMOs.<\/p>\n<p>&nbsp;<\/p>\n<\/div><\/div>\n<\/div>\n\n<div class=\"et_pb_column_4 et_pb_column et-last-child et_flex_column et_pb_column_empty et_pb_css_mix_blend_mode_passthrough et_flex_column_8_24 et_flex_column_8_24_tablet et_flex_column_24_24_phone\"><\/div>\n<\/div>\n<\/div>\n\n<div class=\"et_pb_section_1 et_pb_section et_section_regular et_flex_section\">\n<div class=\"et_pb_row_3 et_pb_row et_flex_row\" id=\"why\">\n<div class=\"et_pb_column_5 et_pb_column et-last-child et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_24_24 et_flex_column_24_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_text_5 et_pb_text et_pb_bg_layout_light et_pb_module et_block_module preset--module--divi-text--b327cbe4-b1d5-4b66-ad37-40c8f2f061ba\"><div class=\"et_pb_text_inner\"><h2>An urgently-needed revolution<\/h2>\n<\/div><\/div>\n\n<div class=\"et_pb_text_6 et_pb_text et_pb_bg_layout_dark et_pb_module et_block_module preset--module--divi-text--1f09816e-184e-4ce5-a4cf-b39c52c423ca\"><div class=\"et_pb_text_inner\" data-et-mv-hidden-tablet=\"true\"><h3><strong>Current lung cancer diagnostics are limited.<\/strong><\/h3>\n<p>Bronchoscopies and biopsies are <a href=\"https:\/\/publications.ersnet.org\/content\/breathe\/7\/4\/324\">invasive, risky procedures<\/a> with <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38835723\/\">technical limitations<\/a>. Biopsy tissue can be limited, and <a href=\"https:\/\/doi.org\/10.1177\/11769351221076062\">poor-quality samples are common<\/a>. 15% of <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S155608642101652X\">screens may miss cancer<\/a>. NGS testing is complex, expensive and slow, <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36191286\/\">delaying decision-making<\/a>. Treatment efficacy may be <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2211568416302170?via%3Dihub\">challenging to understand<\/a>. <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10377917\/\">Relapse may be hard to recognize<\/a>. As cancer progresses, <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5312467\/\">resistance mutations develop<\/a>.<\/p>\n<\/div><\/div>\n<\/div>\n<\/div>\n\n<div class=\"et_pb_row_4 et_pb_row et_flex_row\">\n<div class=\"et_pb_column_6 et_pb_column et-last-child et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_24_24 et_flex_column_24_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_text_7 et_pb_text et_pb_bg_layout_light et_pb_module et_flex_module preset--group--divi-text--divi-font-body--default\"><div class=\"et_pb_text_inner\"><h3 style=\"text-align: left;\"><strong>At every step, the cost of inaction is high.<\/strong><\/h3>\n<p>With about 2.5 million new cases in 2025, the problem is huge: <a href=\"https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/15-trachea-bronchus-and-lung-fact-sheet.pdf\">Lung cancer is the leading cause of cancer<\/a> around the world, and the leading cause of cancer deaths. In 2025, that meant:<\/p>\n<\/div><\/div>\n<\/div>\n<\/div>\n\n<div class=\"et_pb_row_5 et_pb_row et_flex_row\">\n<div class=\"et_pb_column_7 et_pb_column et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_8_24 et_flex_column_8_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_number_counter_0 et_pb_number_counter et_pb_bg_layout_light et_pb_text_align_center et_pb_with_title et_clickable et_pb_module et_flex_module\"><div class=\"percent\"><p><span class=\"percent-value\"><\/span><span class=\"percent-sign\"><\/span><\/p><\/div><h3 class=\"title\">New US cases<\/h3><\/div>\n<\/div>\n\n<div class=\"et_pb_column_8 et_pb_column et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_8_24 et_flex_column_8_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_number_counter_1 et_pb_number_counter et_pb_bg_layout_light et_pb_text_align_center et_pb_with_title et_clickable et_pb_module et_flex_module\"><div class=\"percent\"><p><span class=\"percent-value\"><\/span><span class=\"percent-sign\"><\/span><\/p><\/div><h3 class=\"title\">New EU cases<\/h3><\/div>\n<\/div>\n\n<div class=\"et_pb_column_9 et_pb_column et-last-child et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_8_24 et_flex_column_8_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_number_counter_2 et_pb_number_counter et_pb_bg_layout_light et_pb_text_align_center et_pb_with_title et_clickable et_pb_module et_flex_module\"><div class=\"percent\"><p><span class=\"percent-value\"><\/span><span class=\"percent-sign\"><\/span><\/p><\/div><h3 class=\"title\">New cases in Asia<\/h3><\/div>\n<\/div>\n<\/div>\n\n<div class=\"et_pb_row_6 et_pb_row et_flex_row\">\n<div class=\"et_pb_column_10 et_pb_column et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_2_5 et_flex_column_2_5_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_text_8 et_pb_text et_pb_bg_layout_light et_pb_module et_flex_module preset--group--divi-text--divi-font-body--default\"><div class=\"et_pb_text_inner\"><h3>Most lung cancer patients are <a href=\"https:\/\/www.cancer.org\/cancer\/types\/lung-cancer\/about\/what-is.html\">diagnosed at a late stage, with poor prognosis<\/a>.<\/h3>\n<\/div><\/div>\n<\/div>\n\n<div class=\"et_pb_column_11 et_pb_column et-last-child et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_3_5 et_flex_column_3_5_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_text_9 et_pb_text et_pb_bg_layout_light et_pb_module et_flex_module preset--group--divi-text--divi-font-body--default\"><div class=\"et_pb_text_inner\"><p>There is a clear, urgent unmet need for a rapid, patient-friendly (minimally invasive) diagnostic that accelerates accurate decision-making, saving lives and money. Our first-in-class platform is that diagnostic revolution.<\/p>\n<p>We are enabling a new lung cancer diagnostic category with same-day decision impact and strong reimbursement leverage.\u00a0<\/p>\n<\/div><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n<div class=\"et_pb_section_2 et_pb_section et_section_regular et_block_section\">\n<div class=\"et_pb_row_7 et_pb_row et_block_row\" id=\"technology\">\n<div class=\"et_pb_column_12 et_pb_column et_pb_column_4_4 et-last-child et_block_column et_pb_css_mix_blend_mode_passthrough\">\n<div class=\"et_pb_text_10 et_pb_text et_pb_bg_layout_light et_pb_module et_block_module preset--module--divi-text--b327cbe4-b1d5-4b66-ad37-40c8f2f061ba\"><div class=\"et_pb_text_inner\"><h2>Our technology<\/h2>\n<\/div><\/div>\n\n<div class=\"et_pb_text_11 et_pb_text et_pb_bg_layout_light et_pb_module et_block_module preset--module--divi-text--b327cbe4-b1d5-4b66-ad37-40c8f2f061ba\"><div class=\"et_pb_text_inner\"><h3>A simplified, faster workflow helps more patients get treatment sooner<\/h3>\n<\/div><\/div>\n<\/div>\n<\/div>\n\n<div class=\"et_pb_row_8 et_pb_row et_flex_row\">\n<div class=\"et_pb_column_13 et_pb_column et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_12_24 et_flex_column_12_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_image_1 et_pb_image et_pb_module et_block_module\"><span class=\"et_pb_image_wrap\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/11\/1024-DNA-revisions_RS-Camera_a_i2_i3_i3-probe-orange.png\" width=\"553\" height=\"491\" srcset=\"https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/11\/1024-DNA-revisions_RS-Camera_a_i2_i3_i3-probe-orange.png 553w, https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/11\/1024-DNA-revisions_RS-Camera_a_i2_i3_i3-probe-orange-480x426.png 480w\" sizes=\"(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) 553px, 100vw\" class=\"wp-image-171\" title=\"mockup-2\" \/><\/span><\/div>\n<\/div>\n\n<div class=\"et_pb_column_14 et_pb_column et-last-child et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_12_24 et_flex_column_12_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_text_12 et_pb_text et_pb_bg_layout_light et_pb_module et_block_module preset--module--divi-text--1f09816e-184e-4ce5-a4cf-b39c52c423ca\"><div class=\"et_pb_text_inner\"><h3>Genopsy's easy-to-operate, benchtop-sized, multi-analyte liquid biopsy platform features a 2-hour turnaround from blood draw to report.<\/h3>\n<h3>It's that simple. Here's how:<\/h3>\n<\/div><\/div>\n<\/div>\n<\/div>\n\n<div class=\"et_pb_row_9 et_pb_row et_flex_row\">\n<div class=\"et_pb_column_15 et_pb_column et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_6_24 et_flex_column_12_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_text_13 et_pb_text et_pb_bg_layout_light et_pb_module et_flex_module preset--group--divi-text--divi-font-body--default\"><div class=\"et_pb_text_inner\"><h4><strong>1. Liquid sample collection<\/strong><\/h4>\n<p>Standard blood draw (no imaging or biopsy).<\/p>\n<\/div><\/div>\n<\/div>\n\n<div class=\"et_pb_column_16 et_pb_column et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_6_24 et_flex_column_12_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_text_14 et_pb_text et_pb_bg_layout_light et_pb_module et_flex_module preset--group--divi-text--divi-font-body--default\"><div class=\"et_pb_text_inner\"><h4><strong>2. Capture &amp; detection<\/strong><\/h4>\n<p>Nanowires bind circulating tumor DNA (ctDNA). Tumor-specific probes bind to biomarker locations, and produce measurable signals.<\/p>\n<\/div><\/div>\n<\/div>\n\n<div class=\"et_pb_column_17 et_pb_column et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_6_24 et_flex_column_12_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_text_15 et_pb_text et_pb_bg_layout_light et_pb_module et_flex_module preset--group--divi-text--divi-font-body--default\"><div class=\"et_pb_text_inner\"><h4><strong>3. Automated analysis<\/strong><\/h4>\n<p>Interpretation of biomarker patterns. Can be used with mutations, insertions or deletions (indels), gene fusion, etc.<\/p>\n<\/div><\/div>\n<\/div>\n\n<div class=\"et_pb_column_18 et_pb_column et-last-child et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_6_24 et_flex_column_12_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_text_16 et_pb_text et_pb_bg_layout_light et_pb_module et_flex_module preset--group--divi-text--divi-font-body--default\"><div class=\"et_pb_text_inner\"><h4><strong>4. Actionable diagnostic report<\/strong><\/h4>\n<p>Clear results with a personalized molecular profile, enabling earlier decision-making that helps patients.<\/p>\n<\/div><\/div>\n<\/div>\n<\/div>\n\n<div class=\"et_pb_row_10 et_pb_row et_flex_row\">\n<div class=\"et_pb_column_19 et_pb_column et-last-child et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_24_24 et_flex_column_24_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_text_17 et_pb_text et_pb_bg_layout_light et_pb_module et_flex_module preset--group--divi-text--divi-font-body--default\"><div class=\"et_pb_text_inner\"><h2>The foundations of Genopsy technology<\/h2>\n<\/div><\/div>\n\n<div class=\"et_pb_accordion_0 et_pb_accordion et_pb_module et_flex_module preset--group--divi-accordion--divi-font-body--default\">\n<div class=\"et_pb_accordion_item_0 et_pb_accordion_item et_pb_toggle et_pb_module et_pb_toggle_open et_flex_module preset--group--divi-accordion-item--divi-font-body--default\"><h5 class=\"et_pb_toggle_title\">A simplified and faster workflow (PCR-free detection)<\/h5><div class=\"et_pb_toggle_content et_flex_module\"><p><span>Unlike most conventional approaches (ddPCR, standard NGS) that rely on PCR to amplify trace amounts of ctDNA, Genopsy\u2019s nanowire-based assay directly detects DNA variants and mutations. Our platform does not need complex and time-consuming DNA amplification steps, minimizing amplification-related errors and bias that commonly affect the detection of extremely low-frequency ctDNA mutations. This also enables a much faster turnaround time, with some results available in as little as one hour.<\/span><\/p>\n<\/div><\/div>\n\n<div class=\"et_pb_accordion_item_1 et_pb_accordion_item et_pb_toggle et_pb_module et_pb_toggle_close et_flex_module preset--group--divi-accordion-item--divi-font-body--default\"><h5 class=\"et_pb_toggle_title\">Ultra-high sensitivity for rare mutations<\/h5><div class=\"et_pb_toggle_content et_flex_module\"><p style=\"font-weight: 400;\"><span>The physical properties of our nanowire technology enables highly efficient capture and sensing of target DNA. This allows us to capture short ctDNA fragments (~167bp), with up to 80% efficiency for fragments as small as 100bp \u2013 a critical advantage since ctDNA is typically shorter than non-tumor cfDNA. Genopsy\u2019s unique, thread-like nanowire structures increase contact with rare, tumor-specific biomarkers that circulate in blood, increasing capture yield. More captured DNA helps us better detect mutations.<\/span><span>\u00a0<\/span><\/p>\n<\/div><\/div>\n\n<div class=\"et_pb_accordion_item_2 et_pb_accordion_item et_pb_toggle et_pb_module et_pb_toggle_close et_flex_module preset--group--divi-accordion-item--divi-font-body--default\"><h5 class=\"et_pb_toggle_title\">Multi-omics detection<\/h5><div class=\"et_pb_toggle_content et_flex_module\"><p style=\"font-weight: 400;\">We detect more than point mutations. Our platform leverages locally denatured regions of fragmented ctDNA, as well as transiently open DNA structures that naturally arise during transcription and other regulatory processes. These partially accessible regions expose nucleotide sequences and conformational signatures that reflect not only DNA mutations, but also higher-order regulatory or expression-associated events.<\/p>\n<p style=\"font-weight: 400;\">By targeting these open and accessible structures, our nanowire system can detect signals associated with fusion genes and protein overexpression at the DNA level, even though such biomarkers are typically measured using RNA- or protein-based assays.<\/p>\n<p style=\"font-weight: 400;\">This enables our best-in-class platform to deliver a truly integrated, multi-omic readout within a single assay, eliminating the need for separate workflows for DNA, RNA and protein analysis. We can detect:<\/p>\n<ul>\n<li>DNA mutations: EGFR, KRAS, BRAF, PIK3CA, etc.<\/li>\n<li>RNA fusions: ALK, RET, ROS1, etc.<\/li>\n<li>Protein overexpression markers: PD-L1, MET, OGT, etc.<\/li>\n<\/ul>\n<p><strong>We're just getting started.<\/strong> Our category-defining platform also has extensibility beyond lung cancer. Contact us to learn more.<\/p>\n<\/div><\/div>\n\n<div class=\"et_pb_accordion_item_3 et_pb_accordion_item et_pb_toggle et_pb_module et_pb_toggle_close et_flex_module preset--group--divi-accordion-item--divi-font-body--default\"><h5 class=\"et_pb_toggle_title\">A revolutionary approach<\/h5><div class=\"et_pb_toggle_content et_flex_module\"><p><span style=\"font-weight: 400;\">The Genopsy platform delivers a precise, cost-efficient and rapid liquid biopsy solution that simplifies clinical workflows and significantly improves sensitivity for detecting minimal residual disease (MRD) by eliminating the need for complex molecular steps.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Learn more about how we are changing the landscape of lung cancer diagnosis.<\/span><\/p>\n<\/div><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n<div class=\"et_pb_section_3 et_pb_section et_section_regular et_block_section\">\n<div class=\"et_pb_row_11 et_pb_row et_block_row\" id=\"clinical-advantages\">\n<div class=\"et_pb_column_20 et_pb_column et_pb_column_4_4 et-last-child et_block_column et_pb_css_mix_blend_mode_passthrough\">\n<div class=\"et_pb_text_18 et_pb_text et_pb_bg_layout_light et_pb_module et_block_module preset--module--divi-text--b327cbe4-b1d5-4b66-ad37-40c8f2f061ba\"><div class=\"et_pb_text_inner\"><h2>Clinical advantages<\/h2>\n<\/div><\/div>\n<\/div>\n<\/div>\n\n<div class=\"et_pb_row_12 et_pb_row et_flex_row\">\n<div class=\"et_pb_column_21 et_pb_column et-last-child et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_24_24 et_flex_column_24_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_text_19 et_pb_text et_pb_bg_layout_light et_pb_module et_flex_module preset--group--divi-text--divi-font-body--default\"><div class=\"et_pb_text_inner\"><h3>We\u2019re improving patient care by making diagnoses faster, more accessible and more cost-effective, unlocking earlier treatment that can save and extend lives.<\/h3>\n<\/div><\/div>\n<\/div>\n<\/div>\n\n<div class=\"et_pb_row_13 et_pb_row et_block_row\">\n<div class=\"et_pb_column_22 et_pb_column et_pb_column_1_2 et_block_column et_pb_css_mix_blend_mode_passthrough\">\n<div class=\"et_pb_blurb_0 et_pb_blurb et_pb_bg_layout_dark et_pb_blurb_position_left et_pb_module et_block_module preset--module--divi-blurb--ed6c95a1-34e9-4e11-84f8-e0462d4955ac\"><div class=\"et_pb_blurb_content\"><div class=\"et_pb_main_blurb_image\"><span class=\"et_pb_image_wrap et_pb_only_image_mode_wrap\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/11\/genopsy-clinical-advantages-patient-friendly.png\" width=\"385\" height=\"385\" srcset=\"https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/11\/genopsy-clinical-advantages-patient-friendly.png 385w, https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/11\/genopsy-clinical-advantages-patient-friendly-300x300.png 300w, https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/11\/genopsy-clinical-advantages-patient-friendly-150x150.png 150w\" sizes=\"(max-width: 385px) 100vw, 385px\" class=\"et-waypoint et_pb_animation_off et_pb_animation_off_tablet et_pb_animation_off_phone wp-image-36\" \/><\/span><\/div><div class=\"et_pb_blurb_container\"><h4 class=\"et_pb_module_header\">Patient friendly<\/h4><div class=\"et_pb_blurb_description\"><p><span>Minimally invasive blood draw without CT, bronchoscopy, or invasive biopsy, reducing patient risk and improving patient comfort.<\/span><\/p>\n<\/div><\/div><\/div><\/div>\n<\/div>\n\n<div class=\"et_pb_column_23 et_pb_column et_pb_column_1_2 et-last-child et_block_column et_pb_css_mix_blend_mode_passthrough\">\n<div class=\"et_pb_blurb_1 et_pb_blurb et_pb_bg_layout_dark et_pb_blurb_position_left et_pb_module et_block_module preset--module--divi-blurb--ed6c95a1-34e9-4e11-84f8-e0462d4955ac\"><div class=\"et_pb_blurb_content\"><div class=\"et_pb_main_blurb_image\"><span class=\"et_pb_image_wrap et_pb_only_image_mode_wrap\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/11\/genopsy-clinical-advantages-early-disease-detection.png\" width=\"385\" height=\"385\" srcset=\"https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/11\/genopsy-clinical-advantages-early-disease-detection.png 385w, https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/11\/genopsy-clinical-advantages-early-disease-detection-300x300.png 300w, https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/11\/genopsy-clinical-advantages-early-disease-detection-150x150.png 150w\" sizes=\"(max-width: 385px) 100vw, 385px\" class=\"et-waypoint et_pb_animation_off et_pb_animation_off_tablet et_pb_animation_off_phone wp-image-56\" alt=\"testing multiple targets\" \/><\/span><\/div><div class=\"et_pb_blurb_container\"><h4 class=\"et_pb_module_header\">Early disease detection<\/h4><div class=\"et_pb_blurb_description\"><p>Sensitivity optimized for low tumor burden, complementing imaging. Use with high-risk patients under surveillance and patients with indeterminate nodules.\u00a0<\/p>\n<\/div><\/div><\/div><\/div>\n<\/div>\n<\/div>\n\n<div class=\"et_pb_row_14 et_pb_row et_block_row\">\n<div class=\"et_pb_column_24 et_pb_column et_pb_column_1_2 et_block_column et_pb_css_mix_blend_mode_passthrough\">\n<div class=\"et_pb_blurb_2 et_pb_blurb et_pb_bg_layout_dark et_pb_blurb_position_left et_pb_module et_block_module preset--module--divi-blurb--ed6c95a1-34e9-4e11-84f8-e0462d4955ac\"><div class=\"et_pb_blurb_content\"><div class=\"et_pb_main_blurb_image\"><span class=\"et_pb_image_wrap et_pb_only_image_mode_wrap\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/11\/genopsy-clinical-advantages-testing-multiple-targets.png\" alt=\"testing multiple targets\" width=\"385\" height=\"385\" srcset=\"https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/11\/genopsy-clinical-advantages-testing-multiple-targets.png 385w, https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/11\/genopsy-clinical-advantages-testing-multiple-targets-300x300.png 300w, https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/11\/genopsy-clinical-advantages-testing-multiple-targets-150x150.png 150w\" sizes=\"(max-width: 385px) 100vw, 385px\" class=\"et-waypoint et_pb_animation_off et_pb_animation_off_tablet et_pb_animation_off_phone wp-image-34\" \/><\/span><\/div><div class=\"et_pb_blurb_container\"><h4 class=\"et_pb_module_header\">Tests multiple targets<\/h4><div class=\"et_pb_blurb_description\"><p>Multiplexing automatically detects a panel of ctDNA biomarkers, with extensibility to RNA and proteins.<\/p>\n<\/div><\/div><\/div><\/div>\n<\/div>\n\n<div class=\"et_pb_column_25 et_pb_column et_pb_column_1_2 et-last-child et_block_column et_pb_css_mix_blend_mode_passthrough\">\n<div class=\"et_pb_blurb_3 et_pb_blurb et_pb_bg_layout_dark et_pb_blurb_position_left et_pb_module et_block_module preset--module--divi-blurb--ed6c95a1-34e9-4e11-84f8-e0462d4955ac\"><div class=\"et_pb_blurb_content\"><div class=\"et_pb_main_blurb_image\"><span class=\"et_pb_image_wrap et_pb_only_image_mode_wrap\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/11\/genopsy-clinical-advantages-speed-to-treatment.png\" width=\"385\" height=\"385\" srcset=\"https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/11\/genopsy-clinical-advantages-speed-to-treatment.png 385w, https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/11\/genopsy-clinical-advantages-speed-to-treatment-300x300.png 300w, https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/11\/genopsy-clinical-advantages-speed-to-treatment-150x150.png 150w\" sizes=\"(max-width: 385px) 100vw, 385px\" class=\"et-waypoint et_pb_animation_off et_pb_animation_off_tablet et_pb_animation_off_phone wp-image-58\" \/><\/span><\/div><div class=\"et_pb_blurb_container\"><h4 class=\"et_pb_module_header\">Rapid results<\/h4><div class=\"et_pb_blurb_description\"><p><span>Quick turnaround - 2 hours to results - enables real-time therapy decisions, using less tissue.<\/span><\/p>\n<\/div><\/div><\/div><\/div>\n<\/div>\n<\/div>\n\n<div class=\"et_pb_row_15 et_pb_row et_flex_row\">\n<div class=\"et_pb_column_26 et_pb_column et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_18_24 et_flex_column_18_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_text_20 et_pb_text et_pb_bg_layout_light et_pb_module et_flex_module preset--group--divi-text--divi-font-body--default\"><div class=\"et_pb_text_inner\"><p style=\"font-weight: 400;\"><span style=\"color: #ffffff;\"><strong>No need to \u201cwait and see.\u201d<\/strong> Our best-in-class platform enables decentralized, point-of-care testing in virtually any healthcare setting. <span>We are enabling a new lung cancer diagnostic category with same-day clinical decision-making and strong reimbursement leverage.\u00a0<\/span><\/span><\/p>\n<p style=\"font-weight: 400;\"><span style=\"color: #ffffff;\">High risk populations and patients with indeterminate nodules can get more frequent, minimally invasive, cost-effective assessments. Longitudinal monitoring becomes feasible. Clinicians can get molecular confirmation prior to ordering invasive biopsy procedures.\u00a0<\/span><\/p>\n<p><span style=\"color: #ffffff;\">By complementing imaging and supporting earlier detection, we offer precision medicine insights in nearly every clinical setting. And with p<\/span>latform extensibility beyond lung, the revolution is just beginning.<\/p>\n<\/div><\/div>\n<\/div>\n\n<div class=\"et_pb_column_27 et_pb_column et-last-child et_flex_column et_pb_column_empty et_pb_css_mix_blend_mode_passthrough et_flex_column_6_24 et_flex_column_6_24_tablet et_flex_column_24_24_phone\"><\/div>\n<\/div>\n<\/div>\n\n<div class=\"et_pb_section_4 et_pb_section et_section_regular et_block_section\">\n<div class=\"et_pb_row_16 et_pb_row et_flex_row\">\n<div class=\"et_pb_column_28 et_pb_column et-last-child et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_24_24 et_flex_column_24_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_text_21 et_pb_text et_pb_bg_layout_light et_pb_module et_block_module preset--module--divi-text--aaa7c440-590a-4078-ae0c-0f3c699ac51c\"><div class=\"et_pb_text_inner\"><h2>Healthcare system advantages<\/h2>\n<\/div><\/div>\n\n<div class=\"et_pb_text_22 et_pb_text et_pb_bg_layout_light et_pb_module et_flex_module preset--group--divi-text--divi-font-body--default\"><div class=\"et_pb_text_inner\"><h3>We\u2019re reducing the time, cost and complexity of lung cancer diagnosis, helping providers and healthcare systems deliver better, more efficient care, with strong reimbursement leverage.<\/h3>\n<\/div><\/div>\n\n<div class=\"et_pb_blurb_4 et_pb_blurb et_pb_bg_layout_light et_pb_blurb_position_left et_pb_module et_block_module preset--module--divi-blurb--a4816a31-1364-47b9-9b4d-963c7682387f\"><div class=\"et_pb_blurb_content\"><div class=\"et_pb_main_blurb_image\"><span class=\"et_pb_image_wrap\"><span class=\"et-pb-icon et-waypoint et_pb_animation_off et_pb_animation_off_tablet et_pb_animation_off_phone\">\ue052<\/span><\/span><\/div><div class=\"et_pb_blurb_container\"><div class=\"et_pb_blurb_description\"><h4><span style=\"color: #000000;\">Easy integration into any clinical setting<\/span><\/h4>\n<p>Designed for ease of use even in low-resource community clinics, not just large hospitals. Compatible with existing lab workflows, without requiring Next-Generation Sequencing (NGS)-scale infrastructure or specialty operators.<\/p>\n<\/div><\/div><\/div><\/div>\n\n<div class=\"et_pb_blurb_5 et_pb_blurb et_pb_bg_layout_light et_pb_blurb_position_left et_pb_module et_block_module preset--module--divi-blurb--a4816a31-1364-47b9-9b4d-963c7682387f\"><div class=\"et_pb_blurb_content\"><div class=\"et_pb_main_blurb_image\"><span class=\"et_pb_image_wrap\"><span class=\"et-pb-icon et-waypoint et_pb_animation_off et_pb_animation_off_tablet et_pb_animation_off_phone\">\ue052<\/span><\/span><\/div><div class=\"et_pb_blurb_container\"><div class=\"et_pb_blurb_description\"><h4><span style=\"color: #000000;\">80-95% reduction in time to treatment<\/span><\/h4>\n<p>Reduced from 14\u201328 days under current NGS workflows to approximately 1\u20133 days. Treating patients earlier is better for the pathology of cancer, and better for the mental health of patients.<\/p>\n<\/div><\/div><\/div><\/div>\n\n<div class=\"et_pb_blurb_6 et_pb_blurb et_pb_bg_layout_light et_pb_blurb_position_left et_pb_module et_block_module preset--module--divi-blurb--a4816a31-1364-47b9-9b4d-963c7682387f\"><div class=\"et_pb_blurb_content\"><div class=\"et_pb_main_blurb_image\"><span class=\"et_pb_image_wrap\"><span class=\"et-pb-icon et-waypoint et_pb_animation_off et_pb_animation_off_tablet et_pb_animation_off_phone\">\ue052<\/span><\/span><\/div><div class=\"et_pb_blurb_container\"><div class=\"et_pb_blurb_description\"><h4><span style=\"color: #000000;\"><strong>40-45% reduction in Next-Generation Sequencing (NGS)<\/strong><\/span><\/h4>\n<p>Avoiding NGS lowers costs and laboratory burden. Unlike current practice where nearly all patients undergo NGS, we enable NGS to be used only when it\u2019s needed, helping providers and health systems.<\/p>\n<\/div><\/div><\/div><\/div>\n\n<div class=\"et_pb_blurb_7 et_pb_blurb et_pb_bg_layout_light et_pb_blurb_position_left et_pb_module et_block_module preset--module--divi-blurb--a4816a31-1364-47b9-9b4d-963c7682387f\"><div class=\"et_pb_blurb_content\"><div class=\"et_pb_main_blurb_image\"><span class=\"et_pb_image_wrap\"><span class=\"et-pb-icon et-waypoint et_pb_animation_off et_pb_animation_off_tablet et_pb_animation_off_phone\">\ue052<\/span><\/span><\/div><div class=\"et_pb_blurb_container\"><div class=\"et_pb_blurb_description\"><h4><span style=\"color: #000000;\"><strong>80% reduction in required tissue<\/strong><\/span><\/h4>\n<p>Across the treatment journey, we enable a decrease from 5\u201310 slides and 200\u2013400ng of DNA to only 1\u20132 slides and 50\u2013100ng of DNA, reducing complexity and the strain on histopathology labs.<\/p>\n<\/div><\/div><\/div><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n<div class=\"et_pb_section_5 et_pb_section et_section_regular et_flex_section\">\n<div class=\"et_pb_row_17 et_pb_row et_flex_row\" id=\"about\">\n<div class=\"et_pb_column_29 et_pb_column et-last-child et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_24_24 et_flex_column_24_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_text_23 et_pb_text et_pb_bg_layout_light et_pb_module et_block_module preset--module--divi-text--b327cbe4-b1d5-4b66-ad37-40c8f2f061ba\"><div class=\"et_pb_text_inner\"><h2>Genopsy history<\/h2>\n<\/div><\/div>\n\n<div class=\"et_pb_text_24 et_pb_text et_pb_bg_layout_light et_pb_module et_flex_module preset--group--divi-text--divi-font-body--default\"><div class=\"et_pb_text_inner\"><p><span>A track record of achievement. Positioned for success.<\/span><\/p>\n<\/div><\/div>\n<\/div>\n<\/div>\n\n<div class=\"et_pb_row_18 et_pb_row et_flex_row\">\n<div class=\"et_pb_column_30 et_pb_column et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_4_24 et_flex_column_4_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_heading_0 et_pb_heading et_pb_module et_flex_module\"><div class=\"et_pb_heading_container\"><h5 class=\"et_pb_module_header\">2017 - 2018<\/h5><\/div><\/div>\n<\/div>\n\n<div class=\"et_pb_column_31 et_pb_column et-last-child et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_8_24 et_flex_column_8_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_heading_1 et_pb_heading et_pb_module et_flex_module\"><div class=\"et_pb_heading_container\"><h4 class=\"et_pb_module_header\">Discovery of core technologies and company founding<\/h4><\/div><\/div>\n\n<div class=\"et_pb_text_25 et_pb_text et_pb_bg_layout_light et_pb_module et_flex_module preset--group--divi-text--divi-font-body--default\"><div class=\"et_pb_text_inner\"><p style=\"font-weight: 400;\">Following the discovery of the DNA bubble as a new biomarker, Genopsy Co., Ltd. was established as the first spin-off company from the Korean National Cancer Center.<\/p>\n<\/div><\/div>\n<\/div>\n<\/div>\n\n<div class=\"et_pb_row_19 et_pb_row et_flex_row\">\n<div class=\"et_pb_column_32 et_pb_column et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_4_24 et_flex_column_4_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_heading_2 et_pb_heading et_pb_module et_flex_module\"><div class=\"et_pb_heading_container\"><h5 class=\"et_pb_module_header\">2018 - 2020<\/h5><\/div><\/div>\n<\/div>\n\n<div class=\"et_pb_column_33 et_pb_column et-last-child et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_8_24 et_flex_column_8_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_heading_3 et_pb_heading et_pb_module et_flex_module\"><div class=\"et_pb_heading_container\"><h4 class=\"et_pb_module_header\">Research and technology exploration<\/h4><\/div><\/div>\n\n<div class=\"et_pb_text_26 et_pb_text et_pb_bg_layout_light et_pb_module et_flex_module preset--group--divi-text--divi-font-body--default\"><div class=\"et_pb_text_inner\"><p style=\"font-weight: 400;\">Genopsy received technology transfer, and was subsequently certified as a Venture Company by the Korea Technology Finance Corporation (KIBO).<\/p>\n<p style=\"font-weight: 400;\">Raised $9.3M USD in Series A investment. Research continued into controlling DNA bubble size, and identifying sample and reagent conditions, and experimental methods.<\/p>\n<\/div><\/div>\n<\/div>\n<\/div>\n\n<div class=\"et_pb_row_20 et_pb_row et_flex_row\">\n<div class=\"et_pb_column_34 et_pb_column et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_4_24 et_flex_column_4_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_heading_4 et_pb_heading et_pb_module et_flex_module\"><div class=\"et_pb_heading_container\"><h5 class=\"et_pb_module_header\">2020 - 2024<\/h5><\/div><\/div>\n<\/div>\n\n<div class=\"et_pb_column_35 et_pb_column et-last-child et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_8_24 et_flex_column_8_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_heading_5 et_pb_heading et_pb_module et_flex_module\"><div class=\"et_pb_heading_container\"><h4 class=\"et_pb_module_header\">Research on analytical processes for commercialization<\/h4><\/div><\/div>\n\n<div class=\"et_pb_text_27 et_pb_text et_pb_bg_layout_light et_pb_module et_flex_module preset--group--divi-text--divi-font-body--default\"><div class=\"et_pb_text_inner\"><p style=\"font-weight: 400;\">Intellectual property was registered in key countries. Genopsy established a research institute and advanced DNA bubble-based, non-PCR analytical processes. Development focused on experimental equipment, consumables, and test bed\/engineering samples.<\/p>\n<\/div><\/div>\n<\/div>\n<\/div>\n\n<div class=\"et_pb_row_21 et_pb_row et_flex_row\">\n<div class=\"et_pb_column_36 et_pb_column et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_4_24 et_flex_column_4_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_heading_6 et_pb_heading et_pb_module et_flex_module\"><div class=\"et_pb_heading_container\"><h5 class=\"et_pb_module_header\">2025<\/h5><\/div><\/div>\n<\/div>\n\n<div class=\"et_pb_column_37 et_pb_column et-last-child et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_8_24 et_flex_column_8_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_heading_7 et_pb_heading et_pb_module et_flex_module\"><div class=\"et_pb_heading_container\"><h4 class=\"et_pb_module_header\">Prototype design, research, and development<\/h4><\/div><\/div>\n\n<div class=\"et_pb_text_28 et_pb_text et_pb_bg_layout_light et_pb_module et_flex_module preset--group--divi-text--divi-font-body--default\"><div class=\"et_pb_text_inner\"><p>Development of the Genesys Analysis Platform continued, with prototype performance testing and evaluation, development of prototype reagent kits and the preparation and compilation of technical documentation.<\/p>\n<p>Genopsy US was established in November, 2025.<\/p>\n<\/div><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n<div class=\"et_pb_section_6 et_pb_section et_section_regular et_block_section\">\n<div class=\"et_pb_row_22 et_pb_row et_block_row\" id=\"leadership\">\n<div class=\"et_pb_column_38 et_pb_column et_pb_column_4_4 et-last-child et_block_column et_pb_css_mix_blend_mode_passthrough\">\n<div class=\"et_pb_text_29 et_pb_text et_pb_bg_layout_light et_pb_module et_block_module preset--module--divi-text--b327cbe4-b1d5-4b66-ad37-40c8f2f061ba\"><div class=\"et_pb_text_inner\"><h2>Leadership<\/h2>\n<\/div><\/div>\n\n<div class=\"et_pb_text_30 et_pb_text et_pb_bg_layout_light et_pb_module et_flex_module preset--group--divi-text--divi-font-body--default\"><div class=\"et_pb_text_inner\"><h3 style=\"font-weight: 400;\"><span style=\"color: #ffffff;\">Experts in the field of nanowire DNA technology, liquid biopsy, lung cancer, biotechnology and regulatory affairs.<\/span><\/h3>\n<\/div><\/div>\n<\/div>\n<\/div>\n\n<div class=\"et_pb_row_23 et_pb_row et_flex_row\">\n<div class=\"et_pb_column_39 et_pb_column et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_6_24 et_flex_column_12_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_team_member_0 et_pb_team_member et_pb_bg_layout_light et_pb_module et_grid_module preset--group--divi-team-member--divi-font-body--default\"><div class=\"et_pb_team_member_image et-waypoint et_pb_animation_off\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/12\/Headshot-Dr-Youngnam-Cho-PhD-s.jpeg\" alt=\"Dr. Youngnam Cho, Ph.D.\" width=\"350\" height=\"350\" srcset=\"https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/12\/Headshot-Dr-Youngnam-Cho-PhD-s.jpeg 350w, https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/12\/Headshot-Dr-Youngnam-Cho-PhD-s-300x300.jpeg 300w, https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/12\/Headshot-Dr-Youngnam-Cho-PhD-s-150x150.jpeg 150w\" sizes=\"(max-width: 350px) 100vw, 350px\" class=\"wp-image-254\" title=\"Dr. Youngnam Cho\" \/><\/div><div class=\"et_pb_team_member_description\"><h4 class=\"et_pb_module_header\">Dr. Youngnam Cho, Ph.D.<\/h4><p class=\"et_pb_member_position\">Founder & CEO Genopsy Bio<\/p><\/div><\/div>\n\n<div class=\"et_pb_text_31 et_pb_text et_pb_bg_layout_light et_pb_module et_flex_module preset--group--divi-text--divi-font-body--default\"><div class=\"et_pb_text_inner\"><p><span>Principal Investigator, National Cancer Center Graduate School (Korea).\u00a0<\/span><span>Research expertise includes circulating tumor DNA (ctDNA) and nanoscale biosensors for early disease detection.<\/span><\/p>\n<\/div><\/div>\n<\/div>\n\n<div class=\"et_pb_column_40 et_pb_column et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_6_24 et_flex_column_12_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_team_member_1 et_pb_team_member et_pb_bg_layout_light et_pb_module et_grid_module preset--group--divi-team-member--divi-font-body--default\"><div class=\"et_pb_team_member_image et-waypoint et_pb_animation_off\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/12\/Headshot-DK.jpg\" alt=\"Dan Kim\" width=\"350\" height=\"350\" srcset=\"https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/12\/Headshot-DK.jpg 350w, https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/12\/Headshot-DK-300x300.jpg 300w, https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/12\/Headshot-DK-150x150.jpg 150w\" sizes=\"(max-width: 350px) 100vw, 350px\" class=\"wp-image-224035\" title=\"Dan Kim\" \/><\/div><div class=\"et_pb_team_member_description\"><h4 class=\"et_pb_module_header\">Dan Kim<\/h4><p class=\"et_pb_member_position\">CEO Genopsy - US<\/p><\/div><\/div>\n\n<div class=\"et_pb_text_32 et_pb_text et_pb_bg_layout_light et_pb_module et_flex_module preset--group--divi-text--divi-font-body--default\"><div class=\"et_pb_text_inner\"><p><span>Senior pharma management and commercialization (Roche, Wyeth, <br \/>&amp; Novartis), including the launch of billion-dollar products in US and global markets.<\/span><\/p>\n<\/div><\/div>\n<\/div>\n\n<div class=\"et_pb_column_41 et_pb_column et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_6_24 et_flex_column_12_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_team_member_2 et_pb_team_member et_pb_bg_layout_light et_pb_module et_grid_module preset--group--divi-team-member--divi-font-body--default\"><div class=\"et_pb_team_member_image et-waypoint et_pb_animation_off\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/12\/Headshot-David-Lim-s.jpg\" alt=\"David Lim, Ph.D.\" width=\"350\" height=\"350\" srcset=\"https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/12\/Headshot-David-Lim-s.jpg 350w, https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/12\/Headshot-David-Lim-s-300x300.jpg 300w, https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/12\/Headshot-David-Lim-s-150x150.jpg 150w\" sizes=\"(max-width: 350px) 100vw, 350px\" class=\"wp-image-256\" title=\"David Lim\" \/><\/div><div class=\"et_pb_team_member_description\"><h4 class=\"et_pb_module_header\">David Lim, Ph.D.<\/h4><p class=\"et_pb_member_position\">US Regulatory<\/p><\/div><\/div>\n\n<div class=\"et_pb_text_33 et_pb_text et_pb_bg_layout_light et_pb_module et_flex_module preset--group--divi-text--divi-font-body--default\"><div class=\"et_pb_text_inner\"><p><span>More than two decades of FDA-focused experience, translating scientific innovation into globally compliant, market-ready diagnostics.<\/span><\/p>\n<\/div><\/div>\n<\/div>\n\n<div class=\"et_pb_column_42 et_pb_column et-last-child et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_6_24 et_flex_column_12_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_team_member_3 et_pb_team_member et_pb_bg_layout_light et_pb_module et_grid_module preset--group--divi-team-member--divi-font-body--default\"><div class=\"et_pb_team_member_image et-waypoint et_pb_animation_off\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/12\/Headshot-Robert-Poorvin.jpg\" alt=\"Robert Poorvin\" width=\"350\" height=\"350\" srcset=\"https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/12\/Headshot-Robert-Poorvin.jpg 350w, https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/12\/Headshot-Robert-Poorvin-300x300.jpg 300w, https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/12\/Headshot-Robert-Poorvin-150x150.jpg 150w\" sizes=\"(max-width: 350px) 100vw, 350px\" class=\"wp-image-224013\" title=\"Robert Poorvin\" \/><\/div><div class=\"et_pb_team_member_description\"><h4 class=\"et_pb_module_header\">Robert Poorvin<\/h4><p class=\"et_pb_member_position\">VP of Clinical Technologies<\/p><\/div><\/div>\n\n<div class=\"et_pb_text_34 et_pb_text et_pb_bg_layout_light et_pb_module et_flex_module preset--group--divi-text--divi-font-body--default\"><div class=\"et_pb_text_inner\"><p><span>Senior IT executive with extensive experience in creating new services &amp; products that transform corporations using internal &amp; outsourced resources. <\/span><\/p>\n<\/div><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n<div class=\"et_pb_section_7 et_pb_section et_section_regular et_flex_section\">\n<div class=\"et_pb_row_24 et_pb_row et_flex_row\">\n<div class=\"et_pb_column_43 et_pb_column et-last-child et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_24_24 et_flex_column_24_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_divider_0 et_pb_divider et_pb_space et_pb_divider_position_center et_pb_module\"><div class=\"et_pb_divider_internal\"><\/div><\/div>\n<\/div>\n<\/div>\n\n<div class=\"et_pb_row_25 et_pb_row et_flex_row\" id=\"contact\">\n<div class=\"et_pb_column_44 et_pb_column et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_12_24 et_flex_column_12_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_text_35 et_pb_text et_pb_bg_layout_light et_pb_module et_block_module preset--module--divi-text--b327cbe4-b1d5-4b66-ad37-40c8f2f061ba\"><div class=\"et_pb_text_inner\"><h2 style=\"text-align: left;\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/genopsy-us.com\/wp-content\/uploads\/2025\/11\/Vector-1.png\" width=\"36\" height=\"57\" alt=\"\" class=\"wp-image-148 alignnone size-full\" \/>\u00a0Get in touch<\/h2>\n<\/div><\/div>\n<\/div>\n\n<div class=\"et_pb_column_45 et_pb_column et-last-child et_flex_column et_pb_css_mix_blend_mode_passthrough et_flex_column_12_24 et_flex_column_12_24_tablet et_flex_column_24_24_phone\">\n<div class=\"et_pb_text_36 et_pb_text et_pb_bg_layout_light et_pb_module et_flex_module preset--group--divi-text--divi-font-body--default\"><div class=\"et_pb_text_inner\"><p style=\"font-weight: 400;\"><span style=\"color: #ffffff;\"><a href=\"mailto:info@genopsy-us.com\">info@genopsy-us.com<\/a><\/span><\/p>\n<\/div><\/div>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-9","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/genopsy-us.com\/index.php\/wp-json\/wp\/v2\/pages\/9","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/genopsy-us.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/genopsy-us.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/genopsy-us.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/genopsy-us.com\/index.php\/wp-json\/wp\/v2\/comments?post=9"}],"version-history":[{"count":19,"href":"https:\/\/genopsy-us.com\/index.php\/wp-json\/wp\/v2\/pages\/9\/revisions"}],"predecessor-version":[{"id":224055,"href":"https:\/\/genopsy-us.com\/index.php\/wp-json\/wp\/v2\/pages\/9\/revisions\/224055"}],"wp:attachment":[{"href":"https:\/\/genopsy-us.com\/index.php\/wp-json\/wp\/v2\/media?parent=9"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}